Drug Profile
ICES 13
Alternative Names: ICES-13; Skeletal muscle-derived cells; SMDCsLatest Information Update: 13 Sep 2017
Price :
$50
*
At a glance
- Originator Innovacell Biotechnologie GmbH
- Class Cell therapies; Urologics
- Mechanism of Action Cell replacements; Cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Stress incontinence
Most Recent Events
- 13 Sep 2017 ICES 13 is still in clinical development for Stress incontinence in Austria (Innovacell Biotechnologie AG website, September 2017)
- 20 Apr 2015 Phase-III development is ongoing in Germany, Czech Republic, Poland, Bulgaria, Austria, Italy and United Kingdom